Jeff Eiseman
Long only, deep value, special situations

MannKind Catalysts: Insights About Diabetes Care Metrics And Long-Term Complications

Afrezza is the inhaled insulin developed by MannKind (NASDAQ:MNKD). After the FDA approves Afrezza and after partnership arrangements are finalized, four catalysts will trigger market penetration and commercial success. Three of them involve greater understanding of the significance of (1) how interactive online communities are affecting medical care, (2) how recent research about the physiological processes that result in long-term complications is sparking a paradigm shift that is changing the blood sugar metrics used to guide treatment decisions, and (3) how Afrezza's superior performance on the replacement metrics can protect and enhance the quality of life and long-term health of five groups of people. The fourth catalyst follows logically from the second and third: insurance company acceptance of...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details